10月2日 - ** 制药商泰沙基因治疗公司TSHA.O股价上涨46%，达到4.64美元的三年多新高
** 泰沙基因治疗公司称，美国食品及药物管理局已授予其治疗雷特综合症（一种罕见的遗传性疾病）的实验性基因疗法TSHA-102 "突破性疗法 (link)"称号。
** 美国食品和药物管理局的这一标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物。
** 该公司还表示，FDA 已为关键性试验扫清了障碍，因为它修改了临床计划，将正在进行的研究的第二部分转为注册试验。
** BMO分析师表示："成功的假设似乎是合理且可实现的。
** 包括本交易日的走势在内，该股今年累计上涨了 170
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.